Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Enbrel (etanercept by Year
Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide net selling price change YoY (%) (%)
Amgen Enbrel (etanercept: -36.0% in FY2025.
Latest, FY2025
-36.0%
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03)
Where the FY2025 figure comes from
“Sales decreased 33% for the full year, primarily driven by 36% lower net selling price resulting from increased 340B Program mix, the impact of the U.S.”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Enbrel (etanercept — Rheumatoid Arthritis & Psoriasis) — Worldwide net selling price change YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -36.0% | – | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
Cite this data
StockData. (2026). Amgen Enbrel (etanercept (%), annual FY2025–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-enbrel-price
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.